Scienture Holdings, Inc. (SCNX): M&A transaction — TRxADE HEALTH completes merger with Scienture; issues Series X preferred convertible to common
Scienture Holdings, Inc.
Closed merger with Scienture Inc. on July 25; Scienture holders get 291,555 common shares (19.99% of pre-deal float) and 6,826,713 Series X non-voting convertible preferred shares.
Company to rename to Scienture Holdings, Inc. after stockholder written consent becomes effective (20 days after information statement mailed).
Board expands to 7; Shankar Hariharan and Narasimhan Mani appointed as directors.
CEO and CFO remain; lock-up agreements prohibit transfer of shares for 180 days post preferred stock conversion.
Consulting agreements with Suren Ajjarapu (702,086 common shares) and Prashant Patel (614,325 common shares) effective upon termination of employment.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.